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Background: Hepatocyte nuclear factor-3β (HNF-3β) plays a critical role in hepatocyte differentiation and controls
liver-specific gene expression during the development of hepatocellular carcinoma (HCC), but the molecular basis
of this process has not been fully elucidated. microRNAs (miRNAs) are powerful, post-transcriptional regulators of
gene expression. Whether miRNAs can impact the effects of HNF-3β in HCC is still unknown.
Methods: HNF-3β and miR-141 expression levels were detected in HepG2 cells, using real-time quantitative RT-PCR
(qRT-PCR). Luciferase reporter assays and Western blots were used to validate HNF-3β as a direct target gene of
miR-141. Cell proliferation, invasion, and apoptosis were also examined to confirm whether miR-141 could impact
on HNF-3β in HCC.
Results: In this study, we found that HNF-3β protein levels were consistently upregulated in HCC clinical tissues
compared with matched normal adjacent tissues. However, the mRNA levels of HNF-3β varied in random tissues,
suggesting that a post-transcriptional mechanism was involved in its regulation. We used bioinformatic analyses to
search for miRNAs that could potentially target HNF-3β, and identified specific targeting sites for miR-141 in the
3′-untranslated region (3′-UTR) of the HNF-3β gene. By overexpressing miR-141 in HepG2 cells, we experimentally
validated that miR-141 directly regulated HNF-3β expression. Furthermore, the biological consequences of targeting
HNF-3β by miR-141 were examined using cell proliferation, invasion and apoptosis assays in vitro. We demonstrated
that the repression of HNF-3β by miR-141 suppressed the proliferation and invasion and promoted the apoptosis of
HepG2 cells.
Conclusions: miR-141 functions as a tumor suppressor in HCC cells through the inhibition of HNF-3β translation.
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Table 1 Clinical features of hepatocellular carcinoma
patients
Tumor subtype Pathological stage HBV infection
Case #1 HCC II HBV+(004)
Case #2 HCC II HBV+(005)
Case #3 HCC III HBV+(93.57)
Case #4 HCC II HBV+(>225)
Case #5 HCC I ~ II HBV+(31.83)
Case #6 HCC II HBV+(>225)
Case #7 HCC I ~ II HBV+(25.723)
Case #8 HCC I HBV+(>225)
Case #9 HCC II ~ III HBV+(9.102)
Case #10 HCC III HBV+(11.687)
Case #11 HCC II —(0.001)
Case #12 HCC II HBV+(72.519)
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Hepatocellular carcinoma (HCC) is one of the most lethal
malignancies and is the third-most common cause of
cancer-related mortality in the world [1]. Early-stage HCC
with preserved liver function can be effectively treated by
resection, liver transplantation or percutaneously and with
a more ideal 5-year survival rate [2]. Generally, HCC pro-
gression can be defined by a decrease in differentiation,
the loss of tissue-specific gene expression, acceleration of
cell proliferation and, ultimately, metastasis [3]. Patients
with HCC often exhibit tumor cell invasion and metastasis
before conventional diagnosis [4]. Therefore, it is vital to
study the molecular basis of HCC and explore new thera-
peutic agents.
The maintenance of hepatocyte differentiation and
control of liver-specific gene expression is attributed,
in large part, to hepatocyte nuclear factor 3 (HNF-3).
The HNF-3/forkhead family of transcription factors in
mammals include three genes designated as HNF-3α
(Foxa-1), HNF-3β (Foxa-2) and HNF-3γ (Foxa-3), which
share homology in their winged-helix DNA binding
domains [5]. The HNF-3β gene is located in chromo-
some 20p11.21, and the downregulation of HNF-3β is
associated with apoptotic injury. The overexpression of
HNF-3β decreases apoptosis, whereas siRNA silencing
of HNF-3β increases apoptosis of HepG2 cells [6,7].
Recently, some studies have shown that HNF-3β expres-
sion and activity are regulated at the post-transcriptional
level [8,9]. For example, Baroukh et al. found that
miR-124a can regulate the HNF-3β protein level, but
not the HNF-3β mRNA level in pancreatic beta-cell
lines [8]. However, the mechanisms of HNF-3β, as well
as the clinical and prognostic significance of HNF-3β
expression, have never been thoroughly studied in
HCC.
miRNAs are non-coding, small, endogenous RNAs
approximately 22 nucleotide long that regulate target
gene expression at the post-transcriptional level [10-12].
Mature miRNA may inhibit translation of the targeted
mRNAs or induce their degradation by preferentially
interacting with the 3′-untranslated regions (3′-UTRs)
of target mRNAs [13,14]. Recent studies have demonstrated
that abnormal miRNA expression plays an important role
in the formation of a wide variety of tumors and is directly
involved in the occurrence, development, diagnosis and
staging of HCC [15-17]. Fan et al. [18] found that miR-
122 was downregulated in the HBV-related HCC cell
line HepG2.2.15 and played an important role in HBV-
related hepatocarcinogenesis by targeting DNRG3. Li
et al. [19] found that miR-429 was upregulated in HCC
and that the epigenetic modification of miR-429 could
manipulate liver tumor-initiating cells by targeting the
RBBP4/E2F1/OCT4 axis. Zhao et al. [20] found that
miR-26b suppressed NF-kappa B signaling and, thereby,sensitized HCC cells to doxorubicin-induced apoptosis
by the expression of TAK1 and TAB3.
Although HNF-3β and miRNAs are associated with
HCC carcinogenesis, little is known about the natural
miRNAs that act on HNF-3β. In this study, we found
that HNF-3β was directly regulated by miR-141 in HCC
cells. Furthermore, we showed that miR-141 inhibited
HNF-3β expression to suppress the proliferation and in-
vasion and promote the apoptosis of HCC cells.
Methods
HCC specimens
Twelve HCC patients who underwent primary surgical
resection were enrolled in this study. Paired HCC and ad-
jacent non-tumor tissue specimens were obtained from
consenting patients and were approved by the Medical
Ethics Committee of the Southern Medical University.
None of the patients had received radiotherapy or chemo-
therapy before surgery. Clinical and pathological data, in-
cluding pathological grading and HBV infection are listed
in Table 1. Tissue fragments were immediately frozen in
liquid nitrogen at the time of surgery and stored at −80°C.
Cell culture
The human HCC cell line HepG2 and Huh7 were pur-
chased from the Shanghai Institute of Biochemistry and
Cell Biology of the Chinese Academy of Sciences (Shanghai,
China). The cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM; Gibco, CA, USA) supplemented
with 10% fetal bovine serum (FBS; Gibco) and 1%
Penicillin-Streptomycin (Gibco) within a humidified
atmosphere containing 5% CO2 at 37°C.
RNA isolation and quantitative RT-PCR
Total RNA was extracted from the cultured cells and hu-
man tissues using TRIzol Reagent (Invitrogen, Carlsbad,
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to quantify miRNAs were performed using TaqMan
miRNA probes (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions, and RT-PCR
reactions were carried out using the manufacturer’s rec-
ommendation. Briefly, 1 μg of total RNA was reverse-
transcribed to cDNA using AMV reverse transcriptase
(TaKaRa, Dalian, China) and a stem-loop RT primer
(Applied Biosystems). Quantitative real-time PCR was
performed using a TaqMan PCR kit on an Applied
Biosystems 7500 Sequence Detection System (Applied
Biosystems) with a standard absolute quantification
thermal cycling program. The cycle threshold (CT) data
were determined using fixed threshold settings, and the
relative levels of miRNAs in the cells and tissues were nor-
malized to U6. The amount of miRNA relative to the
internal U6 control was calculated using the 2-ΔΔCT, in
which ΔΔCT = (CT miRNA −CT U6)target − (CT miRNA −
CT U6)control. To quantify the HNF-3β mRNA, 1 μg of total
RNA was reverse-transcribed to cDNA using oligo dT and
Thermoscript (TaKaRa), and the real-time PCR was per-
formed using the RT product, SYBER Green Dye (Invitro-
gen) and specific primers for HNF-3β and β-actin. The
relative amount of the HNF-3β mRNA was normalized
to β-actin, and the sequences of the primers were as fol-
lows: HNF-3β (sense): 5′-CACCACCAGCCCCACAAA-3′;
HNF-3β (antisense): 5′-GGGTAGTGCATCACCTGTTC
GT-3′; β-actin (sense): 5′-GGCGGCACCACCATGTAC
CCT-3′; and β-actin (antisense): 5′-AGGGGCCGGACT
CG TCATACT-3′.
The overexpression of miR-141
Synthetic pre-miR-141 and scrambled negative control
RNA (pre-miR-control) were purchased from Ambion
(Austin, TX, USA). All cells were seeded in 6-well plates
or 60-mm dishes. The following day, when the cells were
approximately 70% confluent, the cells were transfected
with Lipofectamine 2000 (Invitrogen). In each well, equal
amounts of pre-miR-141 or pre-miR-control were used.
The cells were harvested 24 h after transfection for quan-
titative RT-PCR and Western blotting.
Luciferase reporter assay
To test the direct binding of miR-141 to the target gene,
HNF-3β, a luciferase reporter assay was performed as
previously described [21]. The entire 3′-UTR of human
HNF-3β was amplified using PCR with human genomic
DNA as a template. The PCR products were inserted
into the p-MIR-reporter plasmid (Ambion), and the
insertion was confirmed by sequencing. To test the
binding specificity, the sequences that interacted with
the miR-141 seed sequence were mutated (from AGUGUU
to UCACAA), and the mutant HNF-3β 3′-UTR was
inserted into an equivalent luciferase reporter. For theluciferase reporter assays, HepG2 cells were cultured in
24-well plates, and cells in each well were transfected
with 1 μg of firefly luciferase reporter plasmid, 1 μg of
a β-galactosidase (β-gal) expression plasmid (Ambion)
and equal amounts (100 pmol) of pre-miR-141 or pre-
miR-control using Lipofectamine 2000 (Invitrogen). The
β-gal plasmid was used as a transfection control. Twenty-
four hours post-transfection, the cells were assayed using
a luciferase assay kit (Promega, Madison, WI, USA).
Plasmid construction and siRNA interference assay
An siRNA sequence targeting human HNF-3β cDNA
was designed and synthesized by GenePharma (Shanghai,
China); the siRNA sequence was 5′-GAACAUGUCGU
CGUACGUG-3′. A scrambled siRNA was included as a
negative control. A mammalian expression plasmid en-
coding the human HNF-3β open reading frame (pRecei-
ver-M02-HNF-3β) was purchased from GeneCopoeia
(Germantown, MD, USA), and an empty plasmid served
as a negative control. The HNF-3β expression plasmid
and HNF-3β siRNA were transfected into HepG2 cells
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Total RNA and protein
were isolated 24 h post-transfection, and the HNF-3β
mRNA and protein expression levels were assessed using
quantitative RT-PCR and Western blotting.
Protein extraction and western blotting
All cells were rinsed with PBS (pH 7.4) and lysed in
RIPA Lysis buffer (Beyotime, China) supplemented with
a Protease and Phosphatase Inhibitor Cocktail (Thermo
Scientific 78440) on ice for 30 min. The tissue samples
were frozen solid with liquid nitrogen, ground into a
powder and lysed in RIPA Lysis buffer containing the
Protease and Phosphatase Inhibitor Cocktail on ice for
30 min. When necessary, sonication was used to facilitate
lysis. Cell lysates or tissue homogenates were centrifuged
for 10 min (12000 g, 4°C), the supernatant was collected,
and the protein concentration was calculated using a Pierce
BCA protein assay kit (Thermo Scientific, Rockford, IL,
USA). The protein levels were analyzed using Western
blotting with the corresponding antibodies and normal-
ized by probing the same blots with a GAPDH antibody.
The antibodies were purchased from the following sources:
Anti-HNF-3β (Santa Cruz Biotechnology sc-6553, Santa
Cruz, CA, USA) and anti-GAPDH (Santa Cruz Biotechnol-
ogy sc-365062, Santa Cruz, CA, USA). Protein bands were
analyzed using the Bandscan ImageJ software.
Cell proliferation assay
To assess cell proliferation, HepG2 cells were seeded in
triplicate in 96-well plates at a density of 5 × 103 cells
per well in 100 μL of culture medium. The cell prolifera-
tion index was measured using the Cell Counting Kit-8
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24, 36 and 48 h after transfection according to the man-
ufacturer’s instructions.Cell invasion assay
The invasion ability of HepG2 cells transfected with
pre-miR-141 or the HNF-3β overexpression plasmid
was tested in a Transwell Boyden Chamber (6.5 mm,
Costar, USA). The polycarbonate membranes (8-μm pore
size) on the bottom of the upper compartment of the
Transwells were coated with 1% human fibronectin (R&D
systems 1918-FN, USA). The cells were harvested 24 h
after transfection, suspended in FBS-free DMEM culture
medium and added to the upper chamber (4 × 104 cells/
well). At the same time, 0.5 mL of DMEM with 10% FBS
was added to the lower compartment, and the Transwell-
containing plates were incubated for 12 h in a 5% CO2 at-
mosphere that was saturated with H2O. After incubation,
cells that had entered the lower surface of the filter
membrane were fixed with 4% paraformaldehyde for
25 min at room temperature, washed 3 times with dis-
tilled water and stained with 0.1% crystal violet in
0.1 M borate and 2% ethanol for 15 min at room
temperature. Cells remaining on the upper surface of
the filter membrane (non-migrant) were scraped off
gently with a cotton swab. The lower surfaces (with
migrant cells) were imaged using a photomicroscope (5
fields per chamber) (BX51 Olympus, Japan), and the
cells were counted blindly.Apoptosis assays
The apoptosis of HepG2 cells transfected with pre-miR-
141, siRNA or the HNF-3β overexpression plasmid was
tested using an Annexin V-FITC/propidium iodide (PI)
staining assay. HepG2 cells were cultured in 12-well
plates and transfected with pre-miR-141, HNF-3β
siRNA or the HNF-3β overexpression plasmid to induce
apoptosis. The pre-miR-control, control siRNA and
control plasmid served as negative controls. Cells were
cultured overnight with serum-containing complete
medium and serum-depleted medium, and the attached
and floating cells were then harvested. Flow cytometry
analysis of apoptotic cells was carried out using an
Annexin V-FITC/PI staining kit (BD Biosciences, CA,
USA). After washes with cold PBS, the cells were resus-
pended in binding buffer (100 mM HEPES, pH 7.4;
100 mM NaCl; and 25 mM CaCl2) followed by staining
with Annexin V-FITC/PI at room temperature in
darkness for 15 min. Apoptotic cells were then evalu-
ated by gating PI and Annexin V-positive cells on a
fluorescence-activated cell-sorting (FACS) flow cytometer
(BD Biosciences, San Jose, CA). All experiments were per-
formed in triplicate.Statistical analysis
All of the Western blotting images are representative of
at least three independent experiments. Quantitative
RT-PCR, the luciferase reporter, the cell proliferation
and apoptosis assays were performed in triplicate, and
each experiment were repeated several times. The data
that are shown are the mean ± SD of at least three inde-
pendent experiments. The differences were considered
statistically significant at p <0.05 using Student’s t -test.Results
The upregulation of the HNF-3β protein, but not mRNA,
in human HCC tissues
HNF-3β is in a class of liver-enriched transcription factors
that are engaged in the hepatic phenotype. We first deter-
mined the expression patterns of the HNF-3β protein in
HCC tissues. By measuring the levels of the HNF-3β pro-
tein in 12 pairs of HCC tissues using Western blotting, we
showed that the expression levels of the HNF-3β protein
were significantly higher in tumor tissues than the
matched normal tissues (Figure 1A and 1B). Subsequently,
we performed quantitative real-time PCR (qRT-PCR) ana-
lysis to examine the expression levels of the HNF-3β
mRNA in the same tissue samples. We found that the
HNF-3β mRNA level appeared to be irregular in tumor
specimens than that in normal tissue; however, the overall
difference in the HNF-3β mRNA expression level was not
statistically significant (Figure 1C). This disparity between
the HNF-3β protein and mRNA expression in HCC tissues
strongly suggests that a post-transcriptional mechanism is
involved in the regulation of HNF-3β.Identification of conserved miR-141 target sites within
the 3′-UTR of HNF-3β
One important mode of post-transcriptional regulation
is the repression of mRNA transcripts by miRNAs.
miRNAs are, therefore, likely to play a biologically
relevant role in regulating HNF-3β expression in HCC.
Using three publicly available algorithms (TargetScan,
miRanda and PicTar), miR-141 was identified as a candi-
date miRNA that could target HNF-3β. The predicted
interaction between miR-141 and its target site in the
HNF-3β 3′-UTR is illustrated in Figure 2A. As shown
in this figure, miR-141 has one potential target site in the
3′-UTR of the HNF-3β mRNA sequence. The minimum
free energy value of the hybridization is −27.9 kcal/mol, as
determined by RNA hybrid analysis, which is well within
the range of genuine miRNA-target pairs. Moreover,
perfect base-pairing between the seed region (the core
sequence that encompasses the first 2–7 bases of the
mature miRNA) and the cognate targets was predicted.
Furthermore, the miR-141 binding sequences in the
HNF-3β 3′-UTR were highly conserved across species.
Figure 1 The expression of HNF-3β in human HCC tissues. (A) Western blot analysis of the relative HNF-3β protein level in 12 pairs of HCC
tissue (HCT) and normal adjacent tissue (NCT) samples. GAPDH was used as a loading panel. (B) Quantitative analysis of the data in panel (A). (C)
Quantitative RT-PCR analysis of the relative HNF-3β mRNA levels in the same 12 pairs of HCT and NCT samples (mean ± S.D.; * p < 0.05;
*** p < 0.001).
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were inversely correlated with those of HNF-3β in HCC
tissues. We measured the expression levels of miR-141
using qRT-PCR in the above-mentioned 12 pairs of
tissues. As shown in Figure 2B, miR-141 was significantly
lower in human HCC tissues compared with the adjacent
normal tissues, consistent with the notion that miRNAs
should have expression patterns that are opposite to that
of their targets.
Validation of HNF-3β as a direct target of miR-141
We then determined whether the negative regulatory
effect of miR-141 on HNF-3β expression was directly
mediated through the binding of miR-141 to the pre-
sumed site in the 3′-UTR of the HNF-3β mRNA. The
full length HNF-3β 3′-UTR was placed downstream of
the firefly luciferase gene in a reporter plasmid. The
resulting plasmid was transfected into human HCC cell
line HepG2 along with either pre-miR-141 or pre-miR-
control. Pre-miR-141 is synthetic RNA oligonucleotides
that mimic the miR-141 precursor, which can overex-
press miR-141 after being transfected into HepG2 cells.
As expected, the luciferase activity was markedly reduced
in cells transfected with pre-miR-141 when compared to
cells treated with pre-miR-control (Figure 2C). Further-
more, we introduced point mutations into the corre-
sponding complementary sites in the 3′-UTR of HNF-3β
to eliminate the predicted miR-141 binding site. Mutation
in the complementary seed sites nearly fully rescued the
repression of the reporter activity that was caused by the
overexpression of pre-miR-141 (Figure 2C).
The correlation between miR-141 and HNF-3β was
further examined by evaluating the expression of HNF-
3β in the human HCC cell line HepG2 and Huh7 after
overexpression of miR-141. HepG2 and Huh7 cells trans-
fected with pre-miR-141 showed a significantly increased
expression level of mature miR-141 (Figure 2D and 2G).As anticipated, overexpression of miR-141 significantly re-
duced the HNF-3β protein levels in HepG2 and Huh7
cells (Figure 2E and 2F; 2H and 2I). Thus, based on com-
putational predictions, their inverse correlation in human
cancer tissues and the results of cell transfection assays,
HNF-3β was determined to be a miR-141 target.
The effect of miR-141-mediated downregulation of
HNF-3β on cell proliferation, invasion and apoptosis
To investigate the cellular phenotypes that are triggered
by the miR-141-mediated downregulation of HNF-3β,
HepG2 cells were transfected with pre-miR-141, HNF-
3β siRNA or the HNF-3β plasmid, and the changes in
cell proliferation, invasion and apoptosis were analyzed.
Efficient interference of HNF-3β expression could be
achieved by transfection of the HNF-3β siRNA (Figure 3A
and 3B). We then determined the proliferation rates of
HepG2 cells with decreased HNF-3β or overexpressed
miR-141 using the Cell Counting Kit-8. Compared with
the control siRNA-transfected cells, cells transfected with
HNF-3β siRNA proliferated at a significantly lower rate
(Figure 3C). Likewise, a significant reduction of the cell
proliferation rate was observed in cells transfected with
pre-miR-141 (Figure 3D). Subsequently, we investigated
whether overexpression of miR-141–resistant HNF-3β
(HNF-3β ORF) was sufficient to rescue the suppression of
HNF-3β by miR-141 and attenuate the anti-proliferative
effect of miR-141 in hepatoma carcinoma cells. Cells
transfected with the HNF-3β overexpression plasmid
showed increased HNF-3β mRNA and protein levels
(Figure 3E and 3F) and proliferation rate (Figure 3G)
compared to cells transfected with an empty control
plasmid. Consequently, compared to cells transfected
with pre-miR-141, cells transfected with pre-miR-141 and
the HNF-3β overexpression plasmid exhibited significantly
higher proliferation rates (Figure 3H), suggesting that
overexpression of HNF-3β rescued the miR-141-mediated
Figure 2 Prediction and validation of HNF-3β as the target of miR-141. (A) Schematic description of the hypothesized duplexes formed by
the interactions between the HNF-3β 3′-UTR binding site and miR-141. The predicted structure of the base-paired hybrid is diagrammed. Paired
bases are indicated by a black line, and G:U pairs are indicated by three dots. The predicted free energy of the hybrid is indicated. (B) Quantitative
RT-PCR analysis of the relative miR-141 level in 12 pairs of HCC tissues and noncancerous tissue samples. (C) Analysis of luciferase activity. Firefly
luciferase reporters containing either the wild-type (WT) or mutant (MUT) form of the human HNF-3β 3′-UTR were cotransfected into HepG2 cells
with pre-miR-141 or pre-miR-control. At 24 h post-transfection, the cells were assayed using a luciferase assay kit. Firefly luciferase values were
normalized to β-galactoidase activity and plotted as relative luciferase activity. For comparison, the luciferase activity in pre-miR-control-transfected cells
was set as 1. (D) Quantitative RT-PCR analysis of the relative miR-141 expression level in HepG2 cells transfected with pre-miR-141 or pre-miR-control
for 24 h. (E and F) Western bolt analysis of the endogenous HNF-3β protein level in HepG2 cells transfected with pre-miR-141 or pre-miR-control for
24 h. (E): representative image; (F): the result of the quantitative analysis. (G) Quantitative RT-PCR analysis of the relative miR-141 expression level in
Huh7 cells transfected with pre-miR-141 or pre-miR-control for 24 h. (H and I) Western bolt analysis of the endogenous HNF-3β protein level in Huh7
cells transfected with pre-miR-141 or pre-miR-control for 24 h. H: representative image; I: the result of the quantitative analysis. (mean ± S.D.; * p < 0.05;
*** p < 0.001).
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Taken together, the results indicate that miR-141 might
inhibit cell proliferation by silencing HNF-3β.
Furthermore, we assessed the effect of miR-141 and
HNF-3β on the invasion ability of HepG2 cells. The
chamber assays showed that the invasion rate of HepG2cells transfected with pre-miR-141 was significantly
decreased when compared to cells transfected with the
pre-miR-control (Figure 4A). Additionally, the trans-
fection of the HNF-3β siRNA remarkably reduced the
number of HepG2 cells that passed through the Trans-
well chamber, whereas transfection of the HNF-3β
Figure 3 The effect of miR-141-mediated downregulation of HNF-3β on cell proliferation. (A) Quantitative RT-PCR analysis of HNF-3β
mRNA levels in HepG2 cells when transfected with control or HNF-3β siRNA. (B) Western blot analysis of the endogenous HNF-3β protein level in
HepG2 cells when transfected with control or HNF-3β siRNA. Left: representative image; right: quantitative analysis. (C) Cell proliferation assays
were performed 12, 24, 36 and 48 h after transfection of HepG2 cells with scrambled control siRNA or HNF-3β siRNA. (D) Cell proliferation assays
were performed 12, 24, 36 and 48 h after transfection of HepG2 cells with pre-miR-141 or pre-miR-control. (E) Quantitative RT-PCR analysis of the
HNF-3β mRNA level in HepG2 cells transfected with the control or HNF-3β plasmid. (F) Western blot analysis of the HNF-3β protein level in
HepG2 cells transfected with control or HNF-3β plasmid. Left: representative image; right: quantitative analysis. (G) Cell proliferation assays were
performed 12, 24, 36 and 48 h after transfection of HepG2 cells with control or HNF-3β overexpression plasmid. (H) Cell proliferation assays were
performed 12, 24, 36 and 48 h after transfection of HepG2 cells with pre-miR-141, HNF-3β plasmid, or pre-miR-141 and the HNF-3β plasmid
(mean ± S.D.; ** p < 0.01; *** p < 0.001).
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(Figure 4A). However, when cells were co-transfected
with pre-miR-141 and the HNF-3β overexpression plas-
mid, HNF-3β dramatically attenuated the anti-invasion
effect of miR-141 (Figure 4A). These results indicate that
miR-141 might inhibit cell invasion by silencing HNF-3β.
We lastly investigated apoptosis in cells with increased
miR-141 or silenced HNF-3β expression using flow cy-
tometry analysis. The percentage of apoptotic cells in
the pre-miR-141 transfection group was significantly
higher when compared to cells transfected with the pre-
miR-control (Figure 4B). In addition, the transfection of
the HNF-3β siRNA remarkably increased the percentage
of apoptotic cells when compared to cells transfected
with control siRNA, whereas transfection of the HNF-3β
overexpression plasmid decreased apoptosis (Figure 4B).
Moreover, compared with cells transfected with pre-miR-
141 or the HNF-3β plasmid alone, cells co-transfected
with pre-miR-141 and the HNF-3β overexpression plas-
mid exhibited a normal apoptotic level, suggesting that
HNF-3β might reverse the promotive effect of miR-141
on apoptosis. The results indicate that miR-141 might
modulate apoptosis by downregulating HNF-3β.Discussion
HCC is one of the most highly malignant and lethal can-
cers of the world [22]. The development and progression
of HCC is a complicated process that involves the de-
regulation of multiple genes that are essential for cell
biological processes [23,24]. The hepatocyte nuclear factor
3 family consists of transcription factors that are enriched
in liver and contains three members: HNF-3α, HNF-3β
and HNF-3γ [25-27]. The HNF-3 family plays an im-
portant role in many biological processes, such as early
embryonic development, organ formation and metabolism
[28,29]. As one member of the HNF-3 family, HNF-3β is
the first activated gene in the process of embryonic devel-
opment [30-32]. Reports have found that knockout of
HNF-3β in mice can even result in early embryonic death
due to the lack of formation of the normal neural noto-
chord [28]. HNF-3β is present in early stages of the pan-
creas development process, which is essential for pancreas
α terminal differentiation and pancreatic β cells secreting
insulin [33]. HNF-3β mainly exists in the liver; however,
its role in HCC remains to be elucidated. Xu et al. first
reported the upregulation of HNF-3β in clinical HCC
samples [34]. In this study, we found that HNF-3β protein
Figure 4 The effect of miR-141-mediated downregulation of HNF-3β on cell invasion and apoptosis. (A) Transwell analysis of HepG2 cells
treated with equal doses of pre-miR-control, pre-miR-141, scrambled control siRNA, HNF-3β siRNA, scrambled control plasmid, HNF-3β overexpression
plasmid or pre-miR-203 plus the HNF-3β overexpression plasmid. The experiment was repeated three times, and the quantitative analysis is shown in
the right panel. (B) HepG2 cells were transfected with equal doses of pre-miR-control, pre-miR-141, scrambled control siRNA, HNF-3β siRNA, scrambled
control plasmid, HNF-3β overexpression plasmid or pre-miR-203 plus the HNF-3β overexpression plasmid. Apoptosis profiles were analyzed by flow
cytometry, and the quantitative analysis is shown in the right panel (mean ± S.D.; ** p < 0.01; *** p < 0.001).
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sues compared with matched, normal adjacent tissues,
but HNF-3β mRNA levels varied in random tissues,
suggesting that a post-transcriptional mechanism was
involved in its regulation. Furthermore, we showed that
silencing HNF-3β expression could inhibit cell prolifera-
tion and invasion and promote apoptosis in HepG2 cells,
while overexpressing HNF-3β had opposite effects on
HepG2 cells, indicating its role as an essential oncogene
during HCC tumorigenesis.
miRNA is a class of non-coding RNAs that regulates
target gene expression at the post-transcriptional level.
We used bioinformatic analyses to search for miRNAs
that could target HNF-3β and identified miR-141 as a
candidate. miR-141 belongs to the miR-200 family andhas been reported to be decreased and serve as a tumor
suppressor in numerous cancer types [35]. The level of
miR-141 showed an inverse correlation with the protein
expression of hepatoma-derived growth factor (HDGF)
in gastric cancer cells, and overexpression of miR-141
negatively regulated the proliferation and invasion of
gastric cancer cells [36]. Yoshino et al. [37] found that
miR-141 regulated molecular targets and pathways in
human renal cell carcinoma. Zhao et al. [38] reported
that miR-141 could inhibit proliferation and invasion by
targeting mitogen-activated protein kinase isoform 4
(MAP4K4), which is a member of the mammalian
STE20/MAP4K family. Rasheed et al. [39] found that
miR-141 was downregulated in prostate cancer cells and
had an inverse correlation with the protein expression of
Lin et al. BMC Cancer 2014, 14:879 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/879G-protein subunit a-13 (GNA13). Forcing overexpression
of miR-141 negatively regulated the invasion capability of
prostate cancer cells. However, the expression condition
and detailed role of miR-141 in HCC are poorly under-
stood, except that miR-141 has been previously reported
to suppress the migration and invasion of HCC cells by
targeting Tiam1 [40]. In this study, we examined the
expression patterns of miR-141 in human HCC tissues
and showed that the levels of miR-141 were inversely
correlated with those of HNF-3β in HCC tissues. Subse-
quently, we validated that miR-141 directly recognized
the 3′-UTR of the HNF-3β transcript and downregulated
HNF-3β expression. We lastly showed that miR-141
inhibited HNF-3β expression, consequently inhibiting
cell proliferation and invasion and promoting apoptosis in
HepG2 cells. The results delineate a novel regulatory net-
work that employs miR-141 and HNF-3β to fine-tune cell
proliferation, invasion and apoptosis in liver cells. We also
provided evidence that restoration of HNF-3β expression
could reverse miR-141-suppressed cell proliferation and
invasion and miR-141-promoted apoptosis, suggesting
that the targeting of HNF-3β is a mechanism by which
the miR-141 exerts its tumor suppressive function.
Therefore, the modulation of HNF-3β by miR-141 may
explain, at least in part, why the downregulation of
miR-141 during HCC carcinogenesis can promote cancer
progression.
Although miR-141 has already been reported to be
associated with HCC carcinogenesis, this study reveals a
critical role for miR-141 as an inhibitor of cell prolifera-
tion and invasion and promoter of apoptosis in HCC
cells. More importantly, this study identifies miR-141 as
a novel link between the HNF-3β regulatory pathway
and HCC and points the important role of miR-141 as a
tumor suppressor in HCC through the inhibition of
HNF-3β translation. This study also revealed a potential
new target for HCC therapy.Conclusions
In this study, we found that the expression levels of
HNF-3β were significantly higher in HCC clinical tissues
compared with matched normal adjacent tissues. In
addition, we demonstrated for the first time that HNF-
3β is a direct target of miR-141. Finally, we provided
evidence that miR-141 could inhibit the proliferation
and invasion and promote the apoptosis of HCC cells
by silencing HNF-3β. Taken together, our findings provide
the first clues regarding the role of miR-141 as a tumor
suppressor in cancer cells through the inhibition of HNF-
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